Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease. The company also provides interventional access products that are used in dialysis, oncology, and critical care therapies; and cardiac care products, such as diagnostic and intra-aortic balloon catheters, and capital equipment. In addition, it offers anesthesia products, such as pain management products for use in surgical and obstetric procedures; airway management products and related devices for use in pre-hospital emergency and hospital settings; and other pre-hospital emergency products. Further, the company offers surgical products, including Weck Ligation Systems, Weck EFx Fascial Closure Systems, Percutaneous Surgical Systems, Weck Vista bladeless access ports, Deknatel sutures, and Pilling and Kmedic surgical instruments; products for use in acute care settings for diagnostic and therapeutic procedures, and in general and specialty surgical applications; and single-use respiratory, urology, and interventional urology products. Additionally, it provides devices and instruments for other medical device manufacturers, such as custom-engineered extrusions, diagnostic and interventional catheters, balloon sheath/dilator sets and kits, sutures, performance fibers, and bioresorbable resins and fibers. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was founded in 1943 and is headquartered in Wayne, Pennsylvania.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone610-225-6800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.45 billion
Profitability
Miscellaneous
Employees15,200
Next Earnings Date5/2/2019 (Confirmed)
OptionableOptionable
Teleflex (NYSE:TFX) Frequently Asked Questions
What is Teleflex's stock symbol?
Teleflex trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX."
How often does Teleflex pay dividends? What is the dividend yield for Teleflex?
Teleflex declared a quarterly dividend on Thursday, February 21st. Stockholders of record on Friday, March 1st will be given a dividend of $0.34 per share on Friday, March 15th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.49%. The ex-dividend date of this dividend is Thursday, February 28th. View Teleflex's Dividend History.
How were Teleflex's earnings last quarter?
Teleflex Incorporated (NYSE:TFX) released its quarterly earnings results on Thursday, February, 21st. The medical technology company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.76 by $0.01. The medical technology company earned $641.60 million during the quarter, compared to analysts' expectations of $641.06 million. Teleflex had a return on equity of 18.47% and a net margin of 8.20%. The business's revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.44 EPS. View Teleflex's Earnings History.
When is Teleflex's next earnings date?
How can I listen to Teleflex's earnings call?
Teleflex will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
What guidance has Teleflex issued on next quarter's earnings?
Teleflex updated its FY19 earnings guidance on Thursday, February, 21st. The company provided EPS guidance of $10.90-11.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.03. The company issued revenue guidance of +5-6% to approximately $2.57-2.59 billion, compared to the consensus revenue estimate of $2.59 billion.Teleflex also updated its FY 2019 guidance to $10.90-11.10 EPS.
What price target have analysts set for TFX?
8 brokers have issued twelve-month price targets for Teleflex's stock. Their forecasts range from $255.00 to $350.00. On average, they expect Teleflex's share price to reach $316.1250 in the next year. This suggests a possible upside of 13.2% from the stock's current price. View Analyst Price Targets for Teleflex.
What is the consensus analysts' recommendation for Teleflex?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teleflex in the last year. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Teleflex.
What are Wall Street analysts saying about Teleflex stock?
Here are some recent quotes from research analysts about Teleflex stock:
- 1. Needham & Company LLC analysts commented, "TFX is changing its product categories and segments and we have updated our revenue model to reflect the changes. While we are maintaining our prior total revenue and EPS estimates, we are publishing our estimates for the new product categories and segments. We view RePlas as potential sources of upside to TFX’s 2019 guidance and we reiterate our Strong Buy rating." (3/26/2019)
- 2. According to Zacks Investment Research, "Teleflex continues to report a robust improvement in revenues, banking on growth across all segments and geographies. From the fourth quarter 2018, Teleflex’s NeoTract business has started to contribute organically to its top line. We are upbeat about NeoTract’s receipt of Shonin approval from the MHLW in Japan for the UroLift System for the treatment of BPH. This apart, Teleflex announced a major reimbursement milestone for Urolift of receiving a positive coverage decision from health insurer Humana. Vascular solutions synergy is progressing well. Management also seems to be confident about its recently completed Essential Medical buyout. On the flip side, escalating operating expenses are putting pressure on the bottom line. Tough competition and pricing pressure also weigh on the stock. Overall, in the past year, shares of Teleflex consistently outperformed the S&P 500 market." (2/26/2019)
Has Teleflex been receiving favorable news coverage?
News stories about TFX stock have been trending somewhat negative on Wednesday, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Teleflex earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave media coverage about the medical technology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the next few days.
Who are some of Teleflex's key competitors?
Some companies that are related to Teleflex include Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), ABIOMED (ABMD), DexCom (DXCM), Hill-Rom (HRC), Insulet (PODD), ICU Medical (ICUI), Penumbra (PEN), Globus Medical (GMED), Integra Lifesciences (IART), Haemonetics (HAE), Novocure (NVCR) and Tandem Diabetes Care (TNDM).
What other stocks do shareholders of Teleflex own?
Who are Teleflex's key executives?
Teleflex's management team includes the folowing people:
- Mr. Liam J. Kelly, Pres, CEO & Director (Age 52)
- Mr. Thomas E. Powell, Exec. VP & CFO (Age 57)
- Mr. James J. Leyden, VP, Gen. Counsel & Sec. (Age 52)
- Mr. John R. Deren, VP & Chief Accounting Officer
- Mr. Timothy F. Duffy, Chief Information Officer & VP
Who are Teleflex's major shareholders?
Teleflex's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Pennsylvania Trust Co (0.25%), Scout Investments Inc. (0.16%), Strs Ohio (0.13%), Gateway Investment Advisers LLC (0.06%), Retirement Systems of Alabama (0.05%) and Conestoga Capital Advisors LLC (0.03%). Company insiders that own Teleflex stock include Andrew A Krakauer, Benson Smith, Cameron P Hicks, George Babich Jr, Gretchen R Haggerty, John C Heinmiller, John Deren, Stephen K MD Klasko, Stuart A Randle, Thomas Anthony Kennedy and Thomas E Powell. View Institutional Ownership Trends for Teleflex.
Which institutional investors are selling Teleflex stock?
TFX stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Louisiana State Employees Retirement System, New Mexico Educational Retirement Board, Chicago Capital LLC, Tealwood Asset Management Inc., Legacy Private Trust Co., First Hawaiian Bank and Bridge Creek Capital Management LLC. Company insiders that have sold Teleflex company stock in the last year include Benson Smith, Cameron P Hicks, John Deren, Stuart A Randle, Thomas Anthony Kennedy and Thomas E Powell. View Insider Buying and Selling for Teleflex.
Which institutional investors are buying Teleflex stock?
TFX stock was bought by a variety of institutional investors in the last quarter, including Pennsylvania Trust Co, Scout Investments Inc., Avalon Advisors LLC, Virtu Financial LLC, State of Alaska Department of Revenue, Gateway Investment Advisers LLC, Tributary Capital Management LLC and Mercer Global Advisors Inc. ADV. Company insiders that have bought Teleflex stock in the last two years include Andrew A Krakauer, Gretchen R Haggerty and John C Heinmiller. View Insider Buying and Selling for Teleflex.
How do I buy shares of Teleflex?
Shares of TFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teleflex's stock price today?
One share of TFX stock can currently be purchased for approximately $279.24.
How big of a company is Teleflex?
Teleflex has a market capitalization of $12.86 billion and generates $2.45 billion in revenue each year. The medical technology company earns $200.80 million in net income (profit) each year or $9.90 on an earnings per share basis. Teleflex employs 15,200 workers across the globe.
What is Teleflex's official website?
How can I contact Teleflex?
Teleflex's mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The medical technology company can be reached via phone at 610-225-6800 or via email at [email protected]
MarketBeat Community Rating for Teleflex (NYSE TFX)
MarketBeat's community ratings are surveys of what our community members think about Teleflex and other stocks. Vote "Outperform" if you believe TFX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TFX will underperform the S&P 500 over the long term. You may vote once every thirty days.
